| Literature DB >> 35207215 |
Ina Schlichte1,2, Susanne Petri3, Reinhard Dengler3, Thomas Meyer4,5, Aiden Haghikia1,6,7, Stefan Vielhaber1,6, Susanne Vogt1.
Abstract
BACKGROUND: Pain is a common symptom in patients with amyotrophic lateral sclerosis (ALS). Coping plays a central role in adjustment to pain.Entities:
Keywords: amyotrophic lateral sclerosis; depressive symptoms; motor neuron disease; pain; pain coping
Year: 2022 PMID: 35207215 PMCID: PMC8877778 DOI: 10.3390/jcm11040944
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Demographic and clinical data as well as results from patient reported outcomes of ALS patients with and without pain (mean ± SD or number of patients (%), as appropriate).
| Patients with Pain | Patients without Pain | ||
|---|---|---|---|
| Gender (female/male) | 24/60 (28.6/71.4%) | 20/46 (30.3/69.7%) | 0.817 |
| Patient age | 61.2 ± 11.8 | 66.6 ± 8.0 |
|
| Disease duration from diagnosis in months | 33.5 ± 38.5 | 37.7 ± 51.3 | 0.569 |
| Symptom onset | 0.135 | ||
| Bulbar | 14 (16.7%) | 19 (28.8%) | |
| Upper limb | 37 (44%) | 21 (31.8%) | |
| Lower limb | 31 (36.9%) | 22 (33.3%) | |
| Missing information | 2 (2.4%) | 4 (6.1%) | |
| King’s clinical staging | 0.065 | ||
| Stage 1: Symptom onset/functional involvement of first region | 0 | 0 | |
| Stage 2A: Diagnosis | 7 (8.3%) | 5 (7.6%) | |
| Stage 2B: Functional involvement of a second region | 8 (9.5%) | 16 (24.2%) | |
| Stage 3: Functional involvement of a third region | 39 (46.4%) | 23 (34.8%) | |
| Stage 4A: Need for gastrostomy | 4 (4.8%) | 7 (10.6%) | |
| Stage 4B: Need for respiratory support (NIV) | 26 (31%) | 15 (22.7%) | |
| ALSFRS-EX | |||
| Sum score | 36.6 ± 12.9 | 42.6 ± 10.8 |
|
| Bulbar subscore | 11.6 ± 4.8 | 11.23 ± 3.4 | 0.344 |
| Fine motor subscore | 7.7 ± 4.3 | 10.0 ± 4.9 |
|
| Gross motor subscore | 8.2 ± 5.0 | 10.2 ± 4.6 |
|
| Respiratory subscore | 9.1 ± 3.2 | 10.2 ± 2.8 | 0.038 |
| Disease progression rate * | 0.9 ± 1.9 | 0.75 ± 0.9 | 0.639 |
| ADI-12 | |||
| Sum score | 26.1 ± 7.6 | 22.2 ± 7.1 |
|
| Absence of depressive symptoms (<22 points) | 25 (29.8%) | 33 (50%) |
|
| Mild depressive symptoms (22–28 points) | 26 (31%) | 18 (27.3%) | |
| Clinically relevant depressive symptoms (>28 points) | 31 (36.9%) | 14 (21.2%) | |
| ALSAQ-40 subscale score “emotional functioning” | 41.8 ± 22.6 | 30.9 ± 20.2 |
|
NIV: Non-invasive ventilation; ALSFRS-EX: ALS Functional Rating Scale-Extension; ALSAQ: Amyotrophic Lateral Sclerosis Assessment Questionnaire; ADI: ALS Depression Inventory. * Disease progression rate was calculated as (60-sum of ALSFRS-EX)/disease duration from symptom onset to investigation date in months (adapted from [33,40]). Significant p-values are boldfaced. Referring to the ALSFRS-EX subscales, Bonferroni-adjusted p-values 0.05/4 = 0.0125 were deemed statistically significant. Some of these data were published in a previous publication from this study, see [27].
Data referring to the patients’ ratings of pain interference with daily functions and the medication-related pain relief. Values are given as mean ± SD or number of patients (%), as appropriate.
| Patients with Pain ( | |
|---|---|
| Pain interference with daily functions | |
| Normal work | 5.4 ± 3.0 |
| Walking ability | 4.8 ± 2.8 |
| General activity | 4.5 ± 3.2 |
| Sleep | 4.0 ± 3.7 |
| Mood | 4.2 ± 3.1 |
| Enjoyment of life | 3.6 ± 3.7 |
| Relations with other people | 2.9 ± 3.1 |
| Pain-related pharmacotherapy * | |
| Non-opioid analgesics | |
| Opioid analgesics | |
| Tricyclic antidepressants ** | |
| Anticonvulsants |
* This table does not consider any combination of therapies. Thus, the total percentage of patients is higher than 100%. ** Antidepressants refer to their use for analgesic purposes.
Figure 1Use of pain coping strategies in ALS patients with pain, indicating the mean values of the CSQ subscale scores on a scale from 0 “never do that” to 6 “always do that”. The different pain coping strategies are grouped into active (highlighted in light grey) and passive coping strategies (highlighted in grey) and are arranged in descending order of the mean subscale scores within the respective category of coping style.
Figure 2Correlation matrix presenting the correlations between demographic and clinical data as well as the results of the patient-reported outcome measures referring to the ALS patients with pain. For visualization of the degree of the association between the variables, a color scale from shades of red to shades of blue was used, which refers to the interpretation of effect sizes in terms of weak (0.10 to 0.29), moderate (0.30 to 0.49) and strong (0.50 to 1.00). Referring to the four groups of variables (demographic data, clinical variables, measure of affective state and pain-related variables), Bonferroni-adjusted p-values: 0.05/4 = 0.0125 were deemed significant and are boldfaced.
Multiple regression analysis of potential predictors of the average pain intensity ratings according to the Brief Pain Inventory (dependent variable).
| Unstandardized Coefficients | Standardized Coefficients | T | VIF | |||
|---|---|---|---|---|---|---|
| Regression Coefficient B | Standard Error | Beta | ||||
| Gender | −0.521 | 0.465 | −0.119 | −1.120 | 0.266 | 1.279 |
| CSQ subscales | ||||||
| Diverting attention | 0.323 | 0.170 | 0.216 | 1.899 | 0.062 | 1.471 |
| Catastrophizing | 0.621 | 0.160 | 0.529 | 3.873 |
| 2.121 |
| Increasing pain behaviors | 0.086 | 0.196 | 0.054 | 0.439 | 0.662 | 1.699 |
| ADI-12 sum score | −0.019 | 0.033 | −0.078 | −0.593 | 0.555 | 1.973 |
Significant p-values are boldfaced. VIF = variance inflation factor.
Figure 3Scatter plot of the relationship between the CSQ subscale score for “catastrophizing” and the average pain intensity ratings according to the BPI. A linear regression line has been superimposed.
Figure 4Scatter plot of the relationship between the CSQ subscale score for the coping strategy of “catastrophizing” and the ADI-12 sum score as a measure of depressive symptoms. A linear regression line has been superimposed.